876
Participants
Start Date
March 12, 2014
Primary Completion Date
March 27, 2017
Study Completion Date
June 16, 2017
Serelaxin
Intravenous infusion
Placebo
Intravenous infusion
Standard of CareTherapy
This treatment can include but is not limited to intravenous and/or oral diuretics, ACE inhibitors/angiotensin receptor antagonists, β blockers, and aldosterone receptor antagonists, etc.
Novartis Investigative Site, Hazmiyeh
Novartis Investigative Site, Manila
Novartis Investigative Site, Manila
Novartis Investigative Site, Quezon City
Novartis Investigative Site, Quezon City
Novartis Investigative Site, Quezon City
Novartis Investigative Site, Makati City
Novartis Investigative Site, San Juan City
Novartis Investigative Site, Pasig
Novartis Investigative Site, Taipei
Novartis Investigative Site, Bangkok
Novartis Investigative Site, Bangkok
Novartis Investigative Site, Taipei
Novartis Investigative Site, Bangkok
Novartis Investigative Site, Amman
Novartis Investigative Site, Amman
Novartis Investigative Site, Amman
Novartis Investigative Site, Taipei
Novartis Investigative Site, Bundang Gu
Novartis Investigative Site, New Taipei City
Novartis Investigative Site, Yilan
Novartis Investigative Site, Wŏnju
Novartis Investigative Site, Cheongju-si
Novartis Investigative Site, Taoyuan District
Novartis Investigative Site, Muang
Novartis Investigative Site, Taichung
Novartis Investigative Site, Kuala Lumpur
Novartis Investigative Site, Sungai Buloh
Novartis Investigative Site, Changhua
Novartis Investigative Site, Chiang Mai
Novartis Investigative Site, Kuala Lumpur
Novartis Investigative Site, Guangzhou
Novartis Investigative Site, Kuala Lumpur
Novartis Investigative Site, Kuala Lumpur
Novartis Investigative Site, Gwangju
Novartis Investigative Site, Kaohsiung City
Novartis Investigative Site, Kaohsiung City
Novartis Investigative Site, Kota Kinabalu
Novartis Investigative Site, Songkhla
Novartis Investigative Site, Kuching
Novartis Investigative Site, Beijing
Novartis Investigative Site, Beijing
Novartis Investigative Site, Beijing
Novartis Investigative Site, Shenyang
Novartis Investigative Site, Shenyang
Novartis Investigative Site, New Delhi
Novartis Investigative Site, Singapore
Novartis Investigative Site, El Achrafiyé
Novartis Investigative Site, Singapore
Novartis Investigative Site, Shanghai
Novartis Investigative Site, Zhujing
Novartis Investigative Site, Suzhou
Novartis Investigative Site, Tianjin
Novartis Investigative Site, Hangzhou
Novartis Investigative Site, Wenzhou
Novartis Investigative Site, Rajasthan
Novartis Investigative Site, Ahmedabad
Novartis Investigative Site, Vadodara
Novartis Investigative Site, Chongqing
Novartis Investigative Site, Nagpur
Novartis Investigative Site, Nagpur
Novartis Investigative Site, Hyderabad
Novartis Investigative Site, Guangzhou
Novartis Investigative Site, Chennai
Novartis Investigative Site, Busan
Novartis Investigative Site, Xian
Novartis Investigative Site, Lanzhou
Novartis Investigative Site, Kamogawa
Novartis Investigative Site, Saku
Novartis Investigative Site, Yangzhou
Novartis Investigative Site, Shanghai
Novartis Investigative Site, Beirut
Novartis Investigative Site, Nagakute
Novartis Investigative Site, Seto
Novartis Investigative Site, Saijō
Novartis Investigative Site, Chikushino-shi
Novartis Investigative Site, Fukuoka
Novartis Investigative Site, Fukuoka
Novartis Investigative Site, Fukuoka
Novartis Investigative Site, Iizuka
Novartis Investigative Site, Kurume
Novartis Investigative Site, Kurume
Novartis Investigative Site, Ōgaki
Novartis Investigative Site, Kushiro
Novartis Investigative Site, Sapporo
Novartis Investigative Site, Amagasaki
Novartis Investigative Site, Kobe
Novartis Investigative Site, Mito
Novartis Investigative Site, Kanazawa
Novartis Investigative Site, Kan’onjichō
Novartis Investigative Site, Takamatsu
Novartis Investigative Site, Kawasaki
Novartis Investigative Site, Yokohama
Novartis Investigative Site, Yokohama
Novartis Investigative Site, Yokohama
Novartis Investigative Site, Yokohama
Novartis Investigative Site, Kochi
Novartis Investigative Site, Kumamoto
Novartis Investigative Site, Yatsushiro
Novartis Investigative Site, Kyoto
Novartis Investigative Site, Uji
Novartis Investigative Site, Sendai
Novartis Investigative Site, Nakano
Novartis Investigative Site, Ueda
Novartis Investigative Site, Niigata
Novartis Investigative Site, Osaka
Novartis Investigative Site, Kawaguchi
Novartis Investigative Site, Sayama
Novartis Investigative Site, Wako
Novartis Investigative Site, Kusatsu
Novartis Investigative Site, Hamamatsu
Novartis Investigative Site, Kakegawa
Novartis Investigative Site, Akishima
Novartis Investigative Site, Chuo Ku
Novartis Investigative Site, Hachiōji
Novartis Investigative Site, Itabashi-ku
Novartis Investigative Site, Musashino
Novartis Investigative Site, Shinagawa Ku
Novartis Investigative Site, Shinagawa-ku
Novartis Investigative Site, Tanabe
Novartis Investigative Site, Osaka
Novartis Investigative Site, Saitama
Novartis Investigative Site, Beirut
Novartis Investigative Site, Gyeonggi-do
Novartis Investigative Site, Seoul
Novartis Investigative Site, Seoul
Novartis Investigative Site, Seoul
Novartis Investigative Site, Seoul
Novartis Investigative Site, Incheon
Novartis Investigative Site, Seoul
Novartis Investigative Site, Seoul
Novartis Investigative Site, Seoul
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY